134 related articles for article (PubMed ID: 38284191)
1. Eribulin for patients with metastatic extramammary Paget disease: Study protocol for a single-arm phase II trial.
Maeda T; Yanagi T; Tokuchi K; Funakoshi T; Horie N; Isoe T; Ito YM; Sato N; Ujiie H
Exp Dermatol; 2024 Jan; 33(1):e14993. PubMed ID: 38284191
[TBL] [Abstract][Full Text] [Related]
2. Novel ex vivo disease model for extramammary Paget's disease using the cancer tissue-originated spheroid method.
Arita T; Kondo J; Kaneko Y; Tsutsumi M; Kanemaru M; Matsui M; Arakawa Y; Katoh N; Inoue M; Asai J
J Dermatol Sci; 2020 Sep; 99(3):185-192. PubMed ID: 32800410
[TBL] [Abstract][Full Text] [Related]
3. Treatment of extramammary Paget disease of the vulva with imiquimod: a retrospective, multicenter study by the German Colposcopy Network.
Luyten A; Sörgel P; Clad A; Gieseking F; Maass-Poppenhusen K; Lellé RJ; Harter P; Buttmann N; Petry KU
J Am Acad Dermatol; 2014 Apr; 70(4):644-650. PubMed ID: 24433876
[TBL] [Abstract][Full Text] [Related]
4. Serum cytokeratin 19 fragment 21-1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease.
Nakamura Y; Tanese K; Hirai I; Amagai M; Kawakami Y; Funakoshi T
Br J Dermatol; 2019 Sep; 181(3):535-543. PubMed ID: 30791097
[TBL] [Abstract][Full Text] [Related]
5. Extramammary Paget's disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies.
Maeda T; Kitamura S; Nishihara H; Yanagi T
Oncogene; 2020 Sep; 39(36):5867-5875. PubMed ID: 32724160
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of a case of hormone receptor-positive metastatic extramammary Paget disease with tamoxifen.
Isomoto K; Haratani K; Watanabe S; Takeda M; Iwasa T; Nakagawa K
Invest New Drugs; 2022 Feb; 40(1):194-197. PubMed ID: 34463889
[TBL] [Abstract][Full Text] [Related]
7. NECTIN4-targeted antibody-drug conjugate is a potential therapeutic option for extramammary Paget disease.
Tanaka Y; Ito T; Murata M; Tanegashima K; Kaku-Ito Y; Nakahara T
Exp Dermatol; 2024 Mar; 33(3):e15049. PubMed ID: 38509717
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of HpD-PDT for Extramammary Paget's Disease refractory to conventional therapy: A prospective, open-label and single arm pilot study.
Wang D; Wang P; Li C; Zhou Z; Zhang L; Zhang G; Wang X
Photodiagnosis Photodyn Ther; 2022 Mar; 37():102670. PubMed ID: 34883272
[TBL] [Abstract][Full Text] [Related]
9. Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M; Kataoka T; Fujiwara T; Tsukushi S; Takahashi M; Kobayashi E; Yamada Y; Tanaka T; Nezu Y; Hiraga H; Wasa J; Nagano A; Nakano K; Nakayama R; Hamada T; Kawano M; Torigoe T; Sakamoto A; Asanuma K; Morii T; Machida R; Sekino Y; Fukuda H; Oda Y; Ozaki T; Tanaka K
BMC Cancer; 2023 Mar; 23(1):219. PubMed ID: 36890471
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.
Hayashida T; Jinno H; Mori K; Sato H; Matsui A; Sakurai T; Hattori H; Takayama S; Wada M; Takahashi M; Seki H; Seki T; Nagayama A; Matsumoto A; Kitagawa Y
BMC Cancer; 2018 Jun; 18(1):701. PubMed ID: 29954362
[TBL] [Abstract][Full Text] [Related]
11. Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian Cancer.
Landry CA; Blanter J; Ru M; Fasano J; Klein P; Shao T; Bhardwaj A; Tiersten A
Oncology; 2024; 102(1):9-16. PubMed ID: 37598677
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy for metastatic extramammary Paget disease.
Oashi K; Tsutsumida A; Namikawa K; Tanaka R; Omata W; Yamamoto Y; Yamazaki N
Br J Dermatol; 2014 Jun; 170(6):1354-7. PubMed ID: 24329551
[TBL] [Abstract][Full Text] [Related]
13. FOXM1: a new therapeutic target of extramammary Paget disease.
Ito T; Tanaka Y; Kaku-Ito Y; Oda Y; Nakahara T
Sci Rep; 2024 Feb; 14(1):4048. PubMed ID: 38374400
[TBL] [Abstract][Full Text] [Related]
14. Clinical features of pagetoid spread: Analysis of perianal lesions associated with anal canal adenocarcinoma and perianal primary extramammary Paget disease.
Kosano M; Kiniwa Y; Mikoshiba A; Iwaya M; Okuyama R
J Dermatol; 2023 Apr; 50(4):546-550. PubMed ID: 36794662
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel Combined With Cisplatin for Metastatic Extramammary Paget Disease.
Cai H; Xu W; Yu B; Li X; Zhu L; Xu Z; Zhou J; Zheng Y; Zou Q; Zeng Y; Wang X; Xu T
Clin Genitourin Cancer; 2018 Aug; 16(4):e899-e901. PubMed ID: 29685612
[TBL] [Abstract][Full Text] [Related]
16. Topical Combination of Fluorouracil and Calcipotriene as a Palliative Therapy for Refractory Extramammary Paget Disease.
Molina GE; Khalifian S; Mull JL; Chen L; Rosman IS; Faulkner-Jones BE; Ngo KH; Demehri S; Cornelius LA; Wu PA
JAMA Dermatol; 2019 May; 155(5):599-603. PubMed ID: 30785593
[TBL] [Abstract][Full Text] [Related]
17. Cyclin-dependent kinase 4/6 inhibitors suppress tumor growth in extramammary Paget's disease.
Kitamura S; Yanagi T; Maeda T; Ujiie H
Cancer Sci; 2022 Feb; 113(2):802-807. PubMed ID: 34866279
[TBL] [Abstract][Full Text] [Related]
18. Perineal extramammary Paget disease responsive to topical imiquimod.
Cecchi R; Pavesi M; Bartoli L; Brunetti L; Rapicano V
J Dtsch Dermatol Ges; 2010 Jan; 8(1):38-40. PubMed ID: 20096058
[TBL] [Abstract][Full Text] [Related]
19. Extramammary paget disease of the penoscrotal region.
Patwardhan PP; Quiroga-Garza GM
Pathol Res Pract; 2023 Jan; 241():154283. PubMed ID: 36584497
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of low-dose 5-fluorouracil/cisplatin therapy for invasive extramammary Paget's disease.
Kato H; Watanabe S; Kariya K; Nakamura M; Morita A
J Dermatol; 2018 May; 45(5):560-563. PubMed ID: 29446148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
